Track market-moving stories before they get noisy

-

MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT) will hold its earnings call and webcast to discuss 2026 first quarter results at 8:30 a.m. CDT on Friday, April 24, 2026. Investors may access the live webcast on the Company’s web site at investor.sensient.com. Alternatively, investors may join the conference call by contacting Chorus Call Inc. at (844) 492-3726 or (412) 317-1078.

A webcast replay will be available on the Company’s web site following the call. The call transcript will be available on the Company’s web site on or after April 28, 2026.

About Sensient Technologies

Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, and personal care industries. Sensient’s customers range in size from small entrepreneurial businesses to major international manufacturers representing some of the world’s best-known brands. Sensient is headquartered in Milwaukee, Wisconsin.

www.sensient.com

Source: Sensient Technologies Corporation

More News From Sensient Technologies Corporation

Back to Newsroom

-

MILWAUKEE--(BUSINESS WIRE)--The Board of Directors of Sensient Technologies Corporation (NYSE: SXT) has declared a regular quarterly cash dividend on its common stock of $0.41 per share. The cash dividend will be paid on June 1, 2026, to shareholders of record on May 11, 2026.

About Sensient Technologies

Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, and personal care industries. Sensient’s customers range in size from small entrepreneurial businesses to major international manufacturers representing some of the world’s best-known brands. Sensient is headquartered in Milwaukee, Wisconsin.

www.sensient.com

Category: Dividends

Source: Sensient Technologies Corporation

More News From Sensient Technologies Corporation

Back to Newsroom

MILWAUKEE--(BUSINESS WIRE)--Sensient Technologies Corporation (NYSE: SXT), a leading provider of flavors and colors for the food, pharmaceutical, and personal care markets, today reported financial results for the first quarter ended March 31, 2026.

First Quarter Consolidated Results

Reported revenue increased 11.1% to $435.8 million in the first quarter of 2026 versus last year’s first quarter results of $392.3 million. On a local currency basis(1), revenue increased 7.2%. Reported operating income increased 24.7% to $66.7 million compared to $53.5 million recorded in last year’s first quarter. In the first quarter of 2025, the Company recorded $2.9 million of costs related to its Portfolio Optimization Plan versus no costs recorded in the first quarter of 2026. Local currency adjusted operating income(1) and local currency adjusted EBITDA(1) were up 12.2% and 10.4%, respectively, in the first quarter. Reported earnings per share increased 28.4% to $1.04 in the first quarter of 2026 compared to 81 cents in the first quarter of 2025. Local currency adjusted diluted EPS(1) increased 14.0% in the first quarter. “Sensient delivered strong results to start off the year. We executed on our strategy and continue to strengthen our position for the opportunities ahead, particularly in the area of natural colors. I remain very confident about our performance and am pleased to increase our guidance for 2026,” said Paul Manning, Sensient’s Chairman, President, and Chief Executive Officer.

First Quarter Group Results

  Reported Local Currency(1) Revenue Quarter Quarter Flavors & Extracts 4.2%

1.7%

Color 18.1%

12.3%

Asia Pacific 8.0%

4.7%

Total Revenue 11.1%

7.2%

Reported Local Currency Adjusted(1) Operating Income Quarter Quarter Flavors & Extracts 7.0%

5.1%

Color 20.7%

13.2%

Asia Pacific 18.4%

14.5%

Total Operating Income 24.7%

12.2%

  The Flavors & Extracts Group reported first quarter 2026 revenue of $201.8 million, an increase of $8.1 million versus the prior year’s first quarter. The Group’s revenue increase was driven primarily by higher prices and volume growth. Segment operating income was $26.8 million in the first quarter of 2026, an increase of $1.8 million compared to the prior year’s first quarter.

The Color Group reported revenue of $198.2 million in the first quarter of 2026, an increase of $30.4 million compared to the prior year’s first quarter. The Group’s revenue increase was driven by strong volume growth and higher prices across the Group. Segment operating income was $42.1 million in the first quarter of 2026, an increase of $7.2 million compared to the prior year’s first quarter results.

The Asia Pacific Group reported revenue of $45.3 million in the first quarter of 2026, an increase of $3.4 million compared to the prior year’s first quarter. The Group’s revenue increase was driven by strong volume growth and higher prices across the Group. Segment operating income was $11.2 million in the quarter, an increase of $1.7 million compared to the prior year’s first quarter.

Corporate & Other reported operating expenses were $13.3 million in the first quarter of 2026, compared to $15.8 million of operating expenses reported in the prior year’s first quarter. The lower operating expenses were primarily due to Portfolio Optimization Plan costs in the prior year’s first quarter. Local currency adjusted operating expenses(1) for Corporate & Other increased $0.4 million compared to the prior year’s first quarter.

2026 OUTLOOK

  Metric Current Guidance Prior Guidance   Local Currency Revenue(1) High Single-Digit to Double-Digit Growth Mid-Single-Digit to Double-Digit Growth   Local Currency Adjusted EBITDA(1) High Single-Digit to Double-Digit Growth Mid-Single-Digit to Double-Digit Growth   Diluted EPS (GAAP) Between $3.70 and $3.90* Between $3.60 and $3.80*   Local Currency Adjusted Diluted EPS(1) High Single-Digit to Double-Digit Growth Mid-Single-Digit to High Single-Digit Growth   *Based on current exchange rates, foreign currency impact is expected to be immaterial for the year. The Company’s guidance is based on current conditions and economic and market trends in the markets in which the Company operates and is subject to various risks and uncertainties as described below.

USE OF NON-GAAP FINANCIAL MEASURES

The Company’s non-GAAP financial measures eliminate the impact of certain items, which, depending on the measure, include: currency movements, depreciation and amortization, Portfolio Optimization Plan costs, and non-cash share-based compensation. These measures are provided to enhance the overall understanding of the Company’s performance when viewed together with the GAAP results. Refer to “Reconciliation of Non-GAAP Amounts” at the end of this release.

CONFERENCE CALL

The Company will host a conference call to discuss its 2026 first quarter financial results at 8:30 a.m. CDT on Friday, April 24, 2026. To participate in the conference call, contact Chorus Call Inc. at (844) 492-3726 or (412) 317-1078, and ask to join the Sensient Technologies Corporation conference call. Alternatively, the call can be accessed by using the webcast link that is available on the Investor Information section of the Company’s web site at www.sensient.com.

A replay of the call will be available one hour after the end of the conference call through May 1, 2026 by calling (855) 669-9658 and using access code 1602690. An audio replay and written transcript of the call will also be posted on the Investor Information section of the Company’s web site at www.sensient.com on or after April 28, 2026.

This release contains statements that may constitute “forward-looking statements” within the meaning of Federal securities laws including in the quote from our Chairman, President, and Chief Executive Officer and under “2026 Outlook” above. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors concerning the Company’s operations and business environment. Important factors that could cause actual results to differ materially from those suggested by these forward-looking statements and that could adversely affect the Company’s future financial performance include the following: the Company’s ability to manage general business, economic, and capital market conditions, including actions taken by customers in response to such market conditions, and the impact of recessions and economic downturns; the impact of macroeconomic and geopolitical volatility, including inflation and shortages impacting the availability and cost of raw materials, energy, and other supplies, disruptions and delays in the Company’s supply chain, and the conflicts between Russia and Ukraine and in the Middle East; industry, regulatory, legal, and economic factors related to the Company’s domestic and international business; the effects of tariffs, trade barriers, and disputes; the availability and cost of labor, logistics, and transportation; the pace and nature of new product introductions by the Company and the Company’s customers; the Company’s ability to anticipate and respond to changing consumer preferences, changing technologies, and changing regulations; the Company’s ability to successfully implement its growth strategies; the outcome of the Company’s various productivity-improvement and cost-reduction efforts, acquisition and divestiture activities, and Portfolio Optimization Plan; growth in markets for products in which the Company competes; industry and customer acceptance of price increases; actions by competitors; the Company’s ability to enhance its innovation efforts and drive cost efficiencies; currency exchange rate fluctuations; and other factors included in “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and in other documents that the Company files with the SEC. The risks and uncertainties identified above are not the only risks the Company faces. Additional risks and uncertainties not presently known to the Company or that it currently believes to be immaterial also may adversely affect the Company. Should any known or unknown risks and uncertainties develop into actual events, these developments could have material adverse effects on our business, financial condition, and results of operations. This release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. Except to the extent required by applicable laws, the Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied herein will not be realized.

ABOUT SENSIENT TECHNOLOGIES

Sensient Technologies Corporation is a leading global manufacturer and marketer of colors, flavors, and other specialty ingredients. Sensient uses advanced technologies and robust global supply chain capabilities to develop specialized solutions for food and beverages, as well as products that serve the pharmaceutical, nutraceutical, and personal care industries. Sensient’s customers range in size from small entrepreneurial businesses to major international manufacturers representing some of the world’s best-known brands. Sensient is headquartered in Milwaukee, Wisconsin.

www.sensient.com

Sensient Technologies Corporation (In thousands, except percentages and per share amounts) (Unaudited)   Consolidated Statements of Earnings Three Months Ended March 31,   2026

2025

% Change

  Revenue $

435,834

$

392,325

11.1

%

  Cost of products sold 283,146

260,548

8.7

%

Selling and administrative expenses 85,960

78,247

9.9

%

  Operating income 66,728

53,530

24.7

%

Interest expense 7,902

7,341

  Earnings before income taxes 58,826

46,189

Income taxes 14,656

11,727

  Net earnings $

44,170

$

34,462

28.2

%

  Earnings per share of common stock: Basic $

1.04

$

0.82

  Diluted $

1.04

$

0.81

  Average common shares outstanding: Basic 42,294

42,197

  Diluted 42,671

42,469

      Results by Segment Three Months Ended March 31,   Revenue

2026

2025

% Change

  Flavors & Extracts $

201,825

$

193,681

4.2

%

Color 198,176

167,750

18.1

%

Asia Pacific 45,255

41,901

8.0

%

Intersegment elimination (9,422

)

(11,007

)

  Consolidated $

435,834

$

392,325

11.1

%

  Operating Income   Flavors & Extracts $

26,750

$

24,989

7.0

%

Color 42,065

34,852

20.7

%

Asia Pacific 11,180

9,442

18.4

%

Corporate & Other (13,267

)

(15,753

)

  Consolidated $

66,728

$

53,530

24.7

%

Sensient Technologies Corporation (In thousands) (Unaudited)   Consolidated Condensed Balance Sheets March 31,

December 31,

2026

2025

  Cash and cash equivalents $

38,542

$

36,533

Trade accounts receivable 342,295

305,380

Inventories 681,730

678,220

Prepaid expenses and other current assets 58,971

59,717

Fixed assets held for sale -

1,598

Total Current Assets 1,121,538

1,081,448

  Goodwill & intangible assets (net) 446,282

449,827

Property, plant, and equipment (net) 550,555

539,296

Other assets 169,213

173,566

  Total Assets $

2,287,588

$

2,244,137

  Trade accounts payable $

114,222

$

138,344

Short-term borrowings 232

352

Other current liabilities 109,259

124,887

Total Current Liabilities 223,713

263,583

  Long-term debt 767,558

709,232

Accrued employee and retiree benefits 24,163

24,045

Other liabilities 53,273

53,763

Shareholders' Equity 1,218,881

1,193,514

  Total Liabilities and Shareholders' Equity $

2,287,588

$

2,244,137

Sensient Technologies Corporation (In thousands, except per share amounts) (Unaudited)   Consolidated Statements of Cash Flows Three Months Ended March 31, 2026

2025

Cash flows from operating activities: Net earnings $

44,170

$

34,462

Adjustments to arrive at net cash provided by operating activities: Depreciation and amortization 15,538

15,074

Share-based compensation expense 3,776

2,900

Net (gain) loss on assets (305

)

46

Portfolio Optimization Plan costs -

831

Deferred income taxes 1,897

1,282

Changes in operating assets and liabilities: Trade accounts receivable (37,718

)

(20,780

)

Inventories (5,360

)

7,202

Prepaid expenses and other assets (270

)

(8,064

)

Trade accounts payable and other accrued expenses (22,837

)

(25,859

)

Accrued salaries, wages, and withholdings (15,273

)

(21,665

)

Income taxes 2,562

4,989

Other liabilities 203

604

  Net cash used in operating activities (13,617

)

(8,978

)

  Cash flows from investing activities: Acquisition of property, plant, and equipment (28,737

)

(16,854

)

Proceeds from sale of assets 2,016

7

Acquisition of new business -

(4,349

)

Other investing activities (200

)

(88

)

  Net cash used in investing activities (26,921

)

(21,284

)

  Cash flows from financing activities: Proceeds from additional borrowings 140,139

66,449

Debt payments (76,867

)

(10,771

)

Dividends paid (17,426

)

(17,376

)

Other financing activities (3,447

)

(2,341

)

  Net cash provided by financing activities 42,399

35,961

  Effect of exchange rate changes on cash and cash equivalents 148

249

  Net increase in cash and cash equivalents 2,009

5,948

Cash and cash equivalents at beginning of period 36,533

26,626

Cash and cash equivalents at end of period $

38,542

$

32,574

    Supplemental Information Three Months Ended March 31, 2026

2025

  Dividends paid per share $

0.41

$

0.41

Sensient Technologies Corporation

(In thousands, except percentages and per share amounts)

(Unaudited)

  Reconciliation of Non-GAAP Amounts

The Company's results for the three months ended March 31, 2026 and 2025 include adjusted operating income, adjusted net earnings, and adjusted diluted earnings per share, which, in each case, exclude Portfolio Optimization Plan costs.

  Three Months Ended March 31,

2026

2025

% Change

Operating income (GAAP) $

66,728

$

53,530

24.7

%

Portfolio Optimization Plan costs – Cost of products sold -

1,814

Portfolio Optimization Plan costs – Selling and administrative expenses -

1,050

Adjusted operating income $

66,728

$

56,394

18.3

%

  Net earnings (GAAP) $

44,170

$

34,462

28.2

%

Portfolio Optimization Plan costs, before tax -

2,864

Tax impact of Portfolio Optimization Plan costs(1) -

(702

)

Adjusted net earnings $

44,170

$

36,624

20.6

%

  Diluted earnings per share (GAAP) $

1.04

$

0.81

28.4

%

Portfolio Optimization Plan costs, net of tax -

0.05

Adjusted diluted earnings per share $

1.04

$

0.86

20.9

%

  Note: Earnings per share calculations may not foot due to rounding differences.   (1) Tax impact adjustments were determined based on the nature of the underlying non-GAAP adjustments and their relevant jurisdictional tax rates. Results by Segment Three Months Ended March 31, Adjusted

Adjusted

Operating Income 2026

Adjustments(2)

2026

2025

Adjustments(2)

2025

  Flavors & Extracts $

26,750

$

-

$

26,750

$

24,989

$

-

$

24,989

Color 42,065

-

42,065

34,852

-

34,852

Asia Pacific 11,180

-

11,180

9,442

-

9,442

Corporate & Other (13,267

)

-

(13,267

)

(15,753

)

2,864

(12,889

)

  Consolidated $

66,728

$

-

$

66,728

$

53,530

$

2,864

$

56,394

    (2) Adjustments consist of Portfolio Optimization Plan costs. The following table summarizes the percentage change in the 2026 results compared to the 2025 results for the corresponding periods.

  Three Months Ended March 31, 2026

Revenue Total

Foreign

Exchange

Rates

Adjustments(3)

Local

Currency

Adjusted

Flavors & Extracts 4.2

%

2.5

%

N/A

1.7

%

Color 18.1

%

5.8

%

N/A

12.3

%

Asia Pacific 8.0

%

3.3

%

N/A

4.7

%

Total Revenue 11.1

%

3.9

%

N/A

7.2

%

  Operating Income Flavors & Extracts 7.0

%

1.9

%

0.0

%

5.1

%

Color 20.7

%

7.5

%

0.0

%

13.2

%

Asia Pacific 18.4

%

3.9

%

0.0

%

14.5

%

Corporate & Other (15.8

%)

0.0

%

(18.7

%)

2.9

%

Total Operating Income 24.7

%

6.5

%

6.0

%

12.2

%

Diluted Earnings Per Share 28.4

%

7.4

%

7.0

%

14.0

%

Adjusted EBITDA 15.7

%

5.3

%

N/A

10.4

%

  (3) Adjustments consist of Portfolio Optimization Plan costs.

Sensient Technologies Corporation (In thousands, except percentages) (Unaudited)   Reconciliation of Non-GAAP Amounts - Continued The following table summarizes the reconciliation between Operating Income (GAAP) and Adjusted EBITDA for the three months ended March 31, 2026 and 2025.   Three Months Ended March 31,

2026

2025

% Change

Operating income (GAAP) $

66,728

$

53,530

24.7

%

Depreciation and amortization 15,538

15,074

Share-based compensation expense 3,776

2,900

Portfolio Optimization Plan costs, before tax -

2,864

Adjusted EBITDA $

86,042

$

74,368

15.7

%

    The following table summarizes the reconciliation between Debt (GAAP) and Net Debt, and Operating Income (GAAP) and Credit Adjusted EBITDA for the trailing twelve months ended March 31, 2026 and 2025.   March 31,

Debt 2026

2025

Short-term borrowings $

232

$

18,575

Long-term debt 767,558

683,266

Credit Agreement adjustments(4) (20,780

)

(21,165

)

Net Debt $

747,010

$

680,676

  Operating income (GAAP) $

220,326

$

195,703

Depreciation and amortization 61,562

60,694

Share-based compensation expense 14,822

10,989

Portfolio Optimization Plan costs, before tax 12,942

6,683

Other non-operating gains(5) (1,170

)

(871

)

Credit Adjusted EBITDA $

308,482

$

273,198

  Net Debt to Credit Adjusted EBITDA 2.4x 2.5x   (4) Adjustments include cash and cash equivalents, as described in the Company's Fourth Amended and Restated Credit Agreement (Credit Agreement), and certain letters of credit and hedge contracts. (5) Adjustments consist of certain financing transaction costs, certain non-financing interest items, and gains and losses related to certain non-cash, non-operating, and/or non-recurring items as described in the Credit Agreement.   We have included each of these non-GAAP measures in order to provide additional information regarding our underlying operating results and comparable period-over-period performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. These non-GAAP measures should not be considered in isolation. Rather, they should be considered together with GAAP measures and the rest of the information included in this release and our SEC filings. Management internally reviews each of these non-GAAP measures to evaluate performance on a comparative period-to-period basis and to gain additional insight into underlying operating and performance trends, and we believe the information can be beneficial to investors for the same purposes. These non-GAAP measures may not be comparable to similarly titled measures used by other companies. Category: Earnings

Source: Sensient Technologies Corporation

Sensient Technologies Corporation (SXT) Q1 2026 Earnings Call Transcript

Posted by Defense World Staff on Apr 25th, 2026

Sensient Technologies Corporation (NYSE:SXT – Get Free Report) shares gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $99.23, but opened at $108.47. Sensient Technologies shares last traded at $114.1350, with a volume of 218,182 shares trading hands.

The specialty chemicals company reported $1.04 EPS for the quarter, beating the consensus estimate of $0.80 by $0.24. The company had revenue of $435.83 million for the quarter, compared to analyst estimates of $411.39 million. Sensient Technologies had a net margin of 8.34% and a return on equity of 12.82%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.86 earnings per share. Sensient Technologies has set its FY 2026 guidance at 3.700-3.90 EPS.

Sensient Technologies Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Monday, May 11th will be paid a $0.41 dividend. The ex-dividend date is Monday, May 11th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 1.3%. Sensient Technologies’s dividend payout ratio is presently 51.90%.

Key Sensient Technologies News Here are the key news stories impacting Sensient Technologies this week:

Positive Sentiment: Q1 results beat expectations — EPS $1.04 vs. $0.80 consensus and revenue $435.8M vs. $411.4M consensus; revenue +11.1% year-over-year, signaling stronger demand and margin performance. Read More. Positive Sentiment: Company says it has lifted its 2026 outlook after the strong quarter and provided FY‑2026 EPS guidance of $3.70–$3.90, which supports better forward earnings visibility. Read More. Positive Sentiment: Board declared a regular quarterly cash dividend of $0.41 per share (record May 11, payable June 1), a sign of cash-flow support and capital return to shareholders. Read More. Neutral Sentiment: Guidance nuance — the $3.70–$3.90 range overlaps consensus (~$3.72), so while management appears confident, investors should watch upcoming quarters and margin drivers to confirm the raise. (See company press release/slides for detail.) Read More. Wall Street Analysts Forecast Growth A number of brokerages have issued reports on SXT. UBS Group assumed coverage on Sensient Technologies in a report on Wednesday, April 1st. They issued a “buy” rating and a $115.00 price target for the company. Zacks Research raised shares of Sensient Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, April 20th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Sensient Technologies in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $111.67.

View Our Latest Stock Report on SXT

Hedge Funds Weigh In On Sensient Technologies Institutional investors and hedge funds have recently modified their holdings of the business. Salomon & Ludwin LLC boosted its position in Sensient Technologies by 146.2% during the fourth quarter. Salomon & Ludwin LLC now owns 293 shares of the specialty chemicals company’s stock worth $28,000 after purchasing an additional 174 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Sensient Technologies by 313.5% during the 4th quarter. Farther Finance Advisors LLC now owns 306 shares of the specialty chemicals company’s stock worth $29,000 after buying an additional 232 shares during the period. State of Wyoming acquired a new position in shares of Sensient Technologies during the 3rd quarter worth approximately $32,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Sensient Technologies during the 4th quarter valued at approximately $33,000. Finally, Advisors Asset Management Inc. lifted its position in shares of Sensient Technologies by 53.1% during the 4th quarter. Advisors Asset Management Inc. now owns 401 shares of the specialty chemicals company’s stock valued at $38,000 after buying an additional 139 shares in the last quarter. Hedge funds and other institutional investors own 90.86% of the company’s stock.

Sensient Technologies Stock Up 24.1% The stock has a market cap of $5.24 billion, a price-to-earnings ratio of 38.96 and a beta of 0.62. The business’s 50 day moving average is $92.86 and its 200-day moving average is $94.32. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.53 and a current ratio of 4.10.

Sensient Technologies Company Profile (Get Free Report)

Sensient Technologies Corporation is a global leader in the manufacture and supply of colors, flavors and fragrances for a broad range of end-markets. The company develops and produces ingredients that enhance the appearance, taste and scent of products in the food, beverage, nutraceutical, pharmaceutical, personal care and household sectors. Its portfolio includes natural and synthetic colorants, botanical and artificial flavor systems, fragrance compounds and specialty chemical offerings tailored to customer specifications.

Within its flavor and fragrance division, Sensient provides custom formulations for sweet, savory and umami taste profiles along with fragrance blends for personal care and cosmetic applications.

Featured Stories Five stocks we like better than Sensient Technologies Receive News & Ratings for Sensient Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensient Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEConnectOne Bancorp (NASDAQ:CNOB) Hits New 1-Year High on Earnings Beat

NEXT HEADLINE »Intel (NASDAQ:INTC) Trading Up 23.3% on Strong Earnings

Sensient Technologies is capitalizing on regulatory-driven demand for natural colors, with Q1 2026 revenue up 11.1% and the Color Group leading growth. SXT's Color Group achieved 12.3% local currency revenue growth and maintained margins despite heavy capacity investments, driven by complex, higher-margin customer conversions. Management anticipates high-single- to double-digit growth in 2026 adjusted EBITDA and EPS, but rising debt and interest expense warrant close monitoring.

Investors interested in Basic Materials stocks should always be looking to find the best-performing companies in the group. Is Sensient Technologies (SXT - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Basic Materials sector should help us answer this question.

Sensient Technologies is a member of the Basic Materials sector. This group includes 248 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Sensient Technologies is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for SXT's full-year earnings has moved 5.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, SXT has moved about 21.3% on a year-to-date basis. Meanwhile, stocks in the Basic Materials group have gained about 13% on average. This shows that Sensient Technologies is outperforming its peers so far this year.

Another Basic Materials stock, which has outperformed the sector so far this year, is Yara International ASA (YARIY - Free Report) . The stock has returned 42% year-to-date.

In Yara International ASA's case, the consensus EPS estimate for the current year increased 40.9% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).

To break things down more, Sensient Technologies belongs to the Chemical - Specialty industry, a group that includes 44 individual companies and currently sits at #92 in the Zacks Industry Rank. This group has gained an average of 9.1% so far this year, so SXT is performing better in this area.

On the other hand, Yara International ASA belongs to the Fertilizers industry. This 6-stock industry is currently ranked #30. The industry has moved +21.7% year to date.

Investors with an interest in Basic Materials stocks should continue to track Sensient Technologies and Yara International ASA. These stocks will be looking to continue their solid performance.

On June 09, 2026, Sensient Technologies Corp (SXT) shares rose 5.9% to a current price of $119.47. This movement comes amid a 52-week range that saw a high of $

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

For the three-month period ended March 31, 2026, as compared to the same period of 2025:

Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% Biopharma & Data revenue of $53.0 million, an increase of 17% Screening revenue of $41.6 million, and approximately 44,000 Shield screening tests, compared to $5.7 million revenue and 9,000 tests in the prior year period Generated non-GAAP gross margin of 66%, compared to 65% for the first quarter of 2025 Recent Operating Highlights

Presented 38 abstracts at the 2026 American Association for Cancer Research Annual Meeting, highlighting the breadth and strength of the Guardant portfolio Enhanced Guardant360 Tissue capabilities with the addition of whole transcriptome profiling, expanding clinical utility Announced collaboration with Nuvalent to develop companion diagnostics in targeted cancer therapy with initial emphasis on Guardant360 Tissue Received FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer’s VEPPANU for ER+/HER2- ESR1 mutated advanced breast cancer Leveraged InfinityAI real-world evidence to support the approval of Daiichi Sankyo’s ENHERTU Activated direct-to-consumer and influencer campaigns during Colorectal Cancer Awareness Month to drive awareness and demand Launched nationwide, multi-year collaboration with Quest to expand access to Shield and accelerate screening adoption Launched Shield Multi-Cancer Detection (MCD) in Asia through Manulife partnership “Our first-quarter revenue increased 48% year over year, reflecting strong momentum across the Guardant portfolio,” said Helmy Eltoukhy, co-founder and co-CEO. “Oncology testing volumes continued to accelerate, reaching 86,000 in the quarter, up 47% year over year. Guardant360 Liquid and Guardant360 Tissue demonstrated significant growth, and we saw strong receptivity to our expansion into therapy response monitoring with Guardant Reveal. We believe these trends, driven by our Smart platform and InfinityAI offerings, position us well for sustained growth and for extending our leadership in precision oncology.”

“We are pleased with our progress with Shield, including strong volume momentum exiting the first quarter,” said AmirAli Talasaz, co-founder and co-CEO. “We expect sustained volume growth as we further build out our commercial infrastructure and expand collaborations with Quest and other partners. With a disciplined focus on execution as we scale, we are well positioned to broaden our reach in cancer screening and drive long-term value creation.”

First Quarter 2026 Financial Results

Revenue was $301.7 million for the first quarter of 2026, a 48% increase from $203.5 million for the corresponding prior year period. Oncology revenue grew 36% to $205.0 million for the first quarter of 2026, from $150.6 million for the corresponding prior year period, primarily driven by an increase in Oncology test volume, which grew 47% over the prior year period, and an increase in reimbursement for our oncology tests. Screening revenue grew over 600% to $41.6 million for the first quarter of 2026, from $5.7 million for the corresponding prior year period, driven primarily by an increase in Shield screening test volume, which grew to approximately 44,000 tests in the first quarter of 2026, from approximately 9,000 tests in the prior year period. The increase was also attributable to an increase in reimbursement for our Shield screening tests. Biopharma and Data revenue grew 17% to $53.0 million for the first quarter of 2026, from $45.4 million for the corresponding prior year period. Licensing and other revenue was $2.1 million for the first quarter of 2026, compared to $1.9 million for the corresponding prior year period.

Gross profit, or total revenue less cost of revenue, was $196.7 million for the first quarter of 2026, an increase of $68.0 million or 53%, from $128.7 million for the corresponding prior year period. Gross margin, or gross profit divided by total revenue, was 65% for the first quarter of 2026, as compared to 63% for the corresponding prior year period.

Non-GAAP gross profit was $200.1 million for the first quarter of 2026, an increase of $68.8 million or 52%, from $131.3 million for the corresponding prior year period. Non-GAAP gross margin was 66% for the first quarter of 2026, as compared to 65% for the corresponding prior year period.

Operating expenses were $318.1 million for the first quarter of 2026, as compared to $239.8 million for the corresponding prior year period. Non-GAAP operating expenses were $268.1 million for the first quarter of 2026, as compared to $199.6 million for the corresponding prior year period. The year-over-year increase in both operating expenses and non-GAAP operating expenses was primarily related to commercial infrastructure expansion and marketing activities to support the Shield and Oncology growth.

Net loss was $112.1 million for the first quarter of 2026, as compared to $95.2 million for the corresponding prior year period. Net loss per share was $0.85 for the first quarter of 2026, as compared to $0.77 for the corresponding prior year period.

Non-GAAP net loss was $58.7 million for the first quarter of 2026, as compared to $61.1 million for the corresponding prior year period. Non-GAAP net loss per share was $0.45 for the first quarter of 2026, as compared to $0.49 for the corresponding prior year period.

Adjusted EBITDA loss was $58.9 million for the first quarter of 2026, as compared to a $58.5 million loss for the corresponding prior year period.

Free cash flow for the first quarter of 2026 was $(71.2) million, as compared to $(67.1) million for the corresponding prior year period.

Cash, cash equivalents, restricted cash and marketable securities were $1.2 billion as of March 31, 2026.

2026 Guidance

Guardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to full year 2025. This compares to the prior range of $1.25 to $1.28 billion, representing growth of 27% to 30%.

Within this revenue range:

Oncology revenue is now expected to grow in the range of 28% to 29% in 2026, compared to prior guidance of 25% to 27%. Oncology volume is now expected to grow greater than 35% in 2026, compared to prior guidance of approximately 30%. Guardant Health continues to expect Biopharma & Data revenue growth to be in the low double-digit range. Screening revenue is now expected to be in the range of $186 to $198 million, driven by Shield volume of 230,000 to 245,000 tests. This compares to the prior guidance of $162 to $174 million revenue and 210,000 to 225,000 tests. Guardant Health continues to expect full year 2026 non-GAAP gross margin to be in the range of 64% to 65%. Guardant Health now expects total non-GAAP operating expenses to be in the range of $1.05 to $1.07 billion, an increase compared to the prior range of $1.03 to $1.05 billion. Guardant Health continues to expect free cash flow burn to be in the range of $185 to $195 million, an improvement compared to $233 million for the full year 2025.

Webcast Information

Guardant Health will host a conference call to discuss the first quarter 2026 financial results after market close on Thursday, May 7, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investors.guardanthealth.com. The webcast will be archived and available for replay for at least 90 days after the event.

Non-GAAP Measures

Guardant Health has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP research and development expense, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss per share, basic and diluted, adjusted EBITDA, and free cash flow.

We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax payments, contingent consideration, amortization of intangible assets, impairment of non-marketable equity securities, gain on extinguishment of convertible notes, and other non-recurring items.

Adjusted EBITDA is defined as net loss adjusted for interest income; interest expense; other income (expense), net; provision for income taxes; depreciation and amortization expense; stock-based compensation expense and related employer payroll tax payments; contingent consideration; and other non-recurring items. Free cash flow is defined as net cash used in operating activities in the period less purchases of property and equipment in the period.

We believe that the exclusion of certain income and expenses in calculating these non-GAAP financial measures can provide a useful measure for investors when comparing our period-to-period core operating results, and when comparing those same results to that published by our peers. We exclude certain items because we believe that these income and expenses do not reflect expected future operating performance. Additionally, certain items are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. We use these non-GAAP financial measures to evaluate ongoing operations, for internal planning and forecasting purposes, and to manage our business.

These non-GAAP financial measures are not intended to be considered in isolation from, as substitute for, or as superior to, the corresponding financial measures prepared in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not present the full measure of our recorded costs against its revenue. In addition, our definition of the non-GAAP financial measures may differ from non-GAAP measures used by other companies.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

  Guardant Health, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share data)

  Three Months Ended March 31,

2026

2025

Revenue

$

301,665

$

203,471

Costs and operating expenses:

Cost of revenue

104,919

74,723

Research and development expense

91,038

88,521

Sales and marketing expense

169,132

104,316

General and administrative expense

57,926

46,952

Total costs and operating expenses

423,015

314,512

Loss from operations

(121,350

)

(111,041

)

Interest income

11,151

9,112

Interest expense

(1,347

)

(791

)

Other income (expense), net

(157

)

7,851

Loss before provision for income taxes

(111,703

)

(94,869

)

Provision for income taxes

372

290

Net loss

$

(112,075

)

$

(95,159

)

Net loss per share, basic and diluted

$

(0.85

)

$

(0.77

)

Weighted-average shares used in computing net loss per share, basic and diluted

131,273

123,871

  Guardant Health, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share data)

  March 31, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$

989,291

$

378,203

Short-term marketable securities

113,469

823,395

Accounts receivable, net

137,404

137,849

Inventory, net

83,851

85,876

Prepaid expenses and other current assets, net

43,490

40,723

Total current assets

1,367,505

1,466,046

Restricted cash

112,150

111,214

Property and equipment, net

150,035

145,915

Right-of-use assets, net

153,906

158,849

Intangible assets, net

25,543

25,921

Goodwill

77,257

77,257

Other assets, net

28,895

28,457

Total Assets

$

1,915,291

$

2,013,659

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities:

Accounts payable

$

75,034

$

54,442

Accrued compensation

91,326

119,646

Accrued expenses

78,013

77,889

Deferred revenue

47,772

50,753

Total current liabilities

292,145

302,730

Convertible senior notes, net

1,503,471

1,504,000

Long-term operating lease liabilities

173,055

178,463

Other long-term liabilities

127,693

127,773

Total Liabilities

2,096,364

2,112,966

Stockholders’ deficit:

Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 131,514,404 and 130,635,301 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

1

1

Additional paid-in capital

2,930,665

2,900,056

Accumulated other comprehensive loss

(5,152

)

(4,852

)

Accumulated deficit

(3,106,587

)

(2,994,512

)

Total Stockholders’ Deficit

(181,073

)

(99,307

)

Total Liabilities and Stockholders’ Deficit

$

1,915,291

$

2,013,659

  Guardant Health, Inc.

Supplemental Revenue Information

(unaudited)

(in thousands)

  Three Months Ended March 31,

2026

2025

Oncology

$

204,954

$

150,559

Biopharma and data

52,977

45,376

Screening

41,590

5,677

Licensing and other

2,144

1,859

Total revenue

$

301,665

$

203,471

  Reconciliation of Selected GAAP Measures to Non-GAAP Measures

(unaudited)

(in thousands, except per share data)

  Three Months Ended March 31,

2026

2025

GAAP cost of revenue

$

104,919

$

74,723

Amortization of intangible assets

(148

)

(148

)

Stock-based compensation expense and related employer payroll tax payments

(3,211

)

(2,390

)

Non-GAAP cost of revenue

$

101,560

$

72,185

GAAP gross profit

$

196,746

$

128,748

Amortization of intangible assets

148

148

Stock-based compensation expense and related employer payroll tax payments

3,211

2,390

Non-GAAP gross profit

$

200,105

$

131,286

GAAP research and development expense

$

91,038

$

88,521

Stock-based compensation expense and related employer payroll tax payments

(14,449

)

(13,090

)

Contingent consideration

—

(534

)

Non-GAAP research and development expense

$

76,589

$

74,897

GAAP sales and marketing expense

$

169,132

$

104,316

Stock-based compensation expense and related employer payroll tax payments

(14,702

)

(10,189

)

Non-GAAP sales and marketing expense

$

154,430

$

94,127

GAAP general and administrative expense

$

57,926

$

46,952

Amortization of intangible assets

(230

)

(332

)

Stock-based compensation expense and related employer payroll tax payments

(19,509

)

(13,571

)

Contingent consideration

—

(490

)

Other

(1,150

)

(2,000

)

Non-GAAP general and administrative expense

$

37,037

$

30,559

Three Months Ended March 31,

2026

2025

GAAP loss from operations

$

(121,350

)

$

(111,041

)

Amortization of intangible assets

378

480

Stock-based compensation expense and related employer payroll tax payments

51,871

39,240

Contingent consideration

—

1,024

Other

1,150

2,000

Non-GAAP loss from operations

$

(67,951

)

$

(68,297

)

GAAP net loss

$

(112,075

)

$

(95,159

)

Amortization of intangible assets

378

480

Stock-based compensation expense and related employer payroll tax payments

51,871

39,240

Contingent consideration

—

1,024

Impairment of non-marketable equity securities

—

5,000

Gain on extinguishment of convertible notes

—

(13,672

)

Other

1,150

2,000

Non-GAAP net loss

$

(58,676

)

$

(61,087

)

GAAP net loss per share, basic and diluted

$

(0.85

)

$

(0.77

)

Non-GAAP net loss per share, basic and diluted

$

(0.45

)

$

(0.49

)

Weighted-average shares used in computing GAAP and Non-GAAP net loss per share, basic and diluted

131,273

123,871

  Reconciliation of GAAP Net Loss to Adjusted EBITDA

(unaudited)

(in thousands)

  Three Months Ended March 31,

2026

2025

GAAP net loss

$

(112,075

)

$

(95,159

)

Interest income

(11,151

)

(9,112

)

Interest expense

1,347

791

Other expense (income), net

157

(7,851

)

Provision for income taxes

372

290

Depreciation and amortization

9,442

10,236

Stock-based compensation expense and related employer payroll tax payments

51,871

39,240

Contingent consideration

—

1,024

Other

1,150

2,000

Adjusted EBITDA

$

(58,887

)

$

(58,541

)

  Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities

(unaudited)

(in thousands)

  Three Months Ended March 31,

2026

2025

Net cash used in operating activities

$

(65,623

)

$

(62,689

)

Purchases of property and equipment

(5,580

)

(4,459

)

Free cash flow

$

(71,203

)

$

(67,148

)

More News From Guardant Health, Inc.

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs w.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan

The approval also transfers the seven previously approved companion diagnostic indications from Guardant360 CDx to the updated test.

The cancer testing company said Guardant360 Liquid CDx is now the largest FDA-approved liquid biopsy panel and evaluates a genomic footprint that is 100 times wider than the earlier Guardant360 CDx test.

The test combines genomic and epigenomic insights from a single blood sample to help clinicians make more informed treatment decisions.

New Platform Integrates Genomic And Epigenomic InsightsGuardant said the updated test is powered by its proprietary Smart Platform, an AI-enabled multiomic technology platform designed to improve circulating tumor DNA detection sensitivity compared with the previous Guardant360 CDx test.

According to the company, the platform integrates genomic and epigenomic profiling from one blood draw, helping identify clinically actionable information that may not be detected through genomics alone.

Faster Turnaround Time And Expanded Clinical UtilityGuardant said the updated liquid biopsy test can deliver results in as little as seven days. The company noted the test is designed to support treatment selection decisions regardless of tissue availability, therapy line, or practice setting.

The company also stated that Guardant360 Liquid CDx is the first liquid biopsy capable of simultaneously identifying genotype and key phenotype information.

Guardant added that its full oncology testing portfolio has now transitioned to the Smart Platform, which supports multiple cancer care applications across the treatment continuum using a single scalable testing infrastructure.

Price ActionGuardant Health shares were up 8.81% at $106.84 at the time of publication on Wednesday, according to Benzinga Pro.

Over the past month, GH has gained about 10.6% versus a 4.3% rise in the S&P 500 and is down roughly 2% year-to-date compared to the index’s 7.8% gain.

Photo by Tada Images via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated Ameri

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.

Key data that will be presented include:

Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations. Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases. Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval. “Our presence at this year’s ASCO reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum.”

Key Guardant Health and collaborator presentations at ASCO 2026

Presentation

Title

Time / Location

8502

Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study

May 29, 2026 / 1:00 - 4:00 PM CDT

3525 / 279

A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3546 / 313

A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3572 / 339

Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3659 / 426

Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4050 / 33

Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4159 / 142

First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4161 / 144

Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP

May 30, 2026 / 9:00 AM - 12:00 PM CDT

4238 / 221

Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy

May 30, 2026 / 9:00 AM - 12:00 PM CDT

3051 / 188

Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME)

May 30, 2026 / 1:30 - 4:30 PM CDT

3052 / 189

Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study

May 30, 2026 / 1:30 - 4:30 PM CDT

3070 / 207

Cell-free DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients

May 30, 2026 / 1:30 - 4:30 PM CDT

3077 / 214

Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling

May 30, 2026 / 1:30 - 4:30 PM CDT

3105 / 242

Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M)

May 30, 2026 / 1:30 - 4:30 PM CDT

1031 / 145

Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer

June 1, 2026 / 1:30 - 4:30 PM CDT

1095 / 209

Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i)

June 1, 2026 / 1:30 - 4:30 PM CDT

The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2026 can be found on the ASCO website.

About Guardant360® Liquid CDx

The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives.

About Guardant360 Liquid

Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.

About Guardant Reveal

Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.

The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.

About Shield

Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

More News From Guardant Health, Inc.

-

Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEXEOS® (zongertinib tablets)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.

The approval enables Guardant360 CDx, a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a simple blood draw, to identify patients with HER2 (ERBB2) tyrosine kinase domain activating mutations who may be eligible for treatment with HERNEXEOS.

HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test. This indication was approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. More information and full prescribing information can be found at HERNEXEOS.com.

“This approval highlights the growing impact of liquid biopsy across advanced cancer care and underscores the utility of Guardant360 CDx to ensuring more patients can be matched to the right therapy at the right time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant360 CDx has been at the forefront of enabling comprehensive genomic profiling through a simple blood draw, helping clinicians identify actionable mutations in genes such as HER2 with speed and accuracy.”

Guardant360 CDx was the first FDA-approved liquid biopsy that provides comprehensive genomic profiling across multiple tumor types and biomarkers. By detecting tumor-derived alterations in circulating cell-free DNA, the test helps clinicians match patients to appropriate targeted therapies and clinical trials.

“Companion diagnostics are essential to personalized lung cancer care, guiding biomarker-driven treatment decisions,” added Vicky Brown, U.S. Therapeutic Area Head for Oncology and Emerging Areas, Boehringer Ingelheim. “Guardant360 CDx will help identify patients with HER2-mutant advanced non-small cell lung cancer and connect eligible patients to the appropriate targeted therapy when timely treatment decisions matter most.”

NSCLC is the most common type of lung cancer, and a subset of patients harbor HER2 mutations that may be targetable with precision therapies. HER2-mutant NSCLC is an aggressive type of lung cancer that has been associated with a poor prognosis. Blood-based testing offers a faster, less invasive alternative to tissue biopsy, which can be challenging in advanced disease.

This latest FDA approval for Guardant360 CDx marks the 27th CDx indication across multiple tumor types globally, building on the platform’s increasing clinical utility and broad coverage by Medicare and commercial payers, representing more than 300 million covered lives.

For more information about Guardant360 CDx, visit www.guardanthealth.com.

About Guardant360® CDx

Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling. It detects multiple genomic alterations across all solid tumors and is approved as a companion diagnostic for therapies in non-small cell lung cancer, breast cancer, and colorectal cancer.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

More News From Guardant Health, Inc.

Back to Newsroom

Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization March 25, 2026 16:01 ET  | Source: ProKidney

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney’s commercial strategy as the Company advances towards the potential commercialization of rilparencel.

“Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market,” said Bruce Culleton, M.D., CEO of ProKidney. “He brings valuable operational and leadership skills needed to help guide ProKidney through its next phase of growth, including strong depth in nephrology and other specialty markets. As we advance our clinical and regulatory objectives for rilparencel, Greg will play a key role in strengthening our leadership team and positioning rilparencel for potential commercialization.”

Mr. Madison brings more than two decades of executive leadership experience across commercial strategy, general management, launch planning, business development, and company building in both clinical and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Executive Officer of Shield Therapeutics plc, where he redesigned the commercial strategy, identified and led a transformative business development transaction, and raised capital to position the company on a path to profitability. Previously, he was Chief Executive Officer of Melt Pharmaceuticals, creating the company and advancing a novel sublingual combination drug from preclinical to Phase 2. Prior to that, he served as President and CEO of Keryx Biopharmaceuticals, leading its evolution from a clinical to commercial-stage organization, launching a novel iron-based phosphate binder for dialysis patients, and advancing a second indication for iron deficiency anemia. Earlier in his career, Mr. Madison was Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals, and Vice President/General Manager of the Global Renal Business at Genzyme, where he helped drive Renagel/Renvela to blockbuster status with over $1 billion in annual revenue.

“ProKidney is developing a truly novel cell therapy with the potential to address a profound unmet need for patients with advanced CKD and diabetes,” said Greg Madison. “As a potential first cell therapy for CKD patients and nephrologists, I am excited to join the Company at such an important time. I look forward to working alongside Bruce and the broader team to shape the commercial strategy, organization, and execute the plans needed to support the potential launch of rilparencel.”

About Chronic Kidney Disease
CKD is a progressive condition characterized by the gradual decline of kidney function, which can ultimately lead to end-stage kidney disease (ESKD) requiring dialysis or transplantation. An estimated 37 million adults in the U.S. have CKD, though many remain undiagnosed in the early stages. Diabetes is the leading cause of CKD, and individuals with both conditions face significantly elevated risks of cardiovascular events, hospitalization, and mortality. ProKidney is developing rilparencel for patients with Stage 3b/4 CKD and diabetes, a population that includes over 1 million people in the U.S. While current treatment options aim to slow disease progression, there remains a substantial unmet need for therapies that can stabilize kidney function and delay or prevent the need for dialysis in patients with advanced CKD.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the advancement of our clinical and regulatory objectives for rilparencel and, if approved, potential commercialization of rilparencel. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact
Audra Friis
[email protected]

May 15, 2026 11:45 ET  | Source: ProKidney

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology (CJASN) in January 2026Ended Q1 2026 with $224.9 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the first quarter ended March 31, 2026, and provided business highlights.

“As we progress through 2026, we continue to build on the momentum established last year through positive Phase 2 REGEN-007 results, alignment with the FDA on the accelerated approval pathway, and meaningful progress on Phase 3 PROACT 1 study enrollment,” said Bruce Culleton, M.D., CEO of ProKidney. “We expect to complete enrollment in PROACT 1 this year, positioning us to deliver pivotal eGFR slope topline results in the second quarter of 2027. Our mission remains highly focused on advancing a potential new treatment option for patients with advanced CKD and diabetes at high risk of kidney failure, an area of significant unmet medical need.”

Business Highlights

Phase 3 REGEN-006 (PROACT 1) — Pivotal Study

Enrollment: On track to complete enrollment for the surrogate (eGFR slope) endpoint in mid-2026Topline readout: Pivotal results expected in Q2 2027Study Power 90% power to detect an effect size of 1.75 mL/min/1.73m² in annualized eGFR slope80% power to detect an effect size of 1.5 mL/min/1.73m² in annualized eGFR slope FDA Alignment: Under rilparencel’s regenerative medicine advanced therapy (RMAT) designation, the U.S. Food and Drug Administration (FDA) confirmed in a prior Type B meeting that a rilparencel effect size of 1.5 mL/min/1.73m² per year would be an acceptable demonstration of efficacy in patients receiving appropriate standard of carePhase 2 REGEN-007 Data: In Group 1, bilateral kidney injections with rilparencel were associated with a 4.6 mL/min/1.73m² improvement in the annual decline in eGFR slope in the pre-injection period versus the period after the last rilparencel injection
Regulatory Position

July 2025 Type B meeting: FDA confirmed that eGFR slope in patients from the ongoing PROACT 1 study can serve as the surrogate endpoint and primary basis for a Biologics License Application (BLA) submission under the accelerated approval pathwayFDA also confirmed that PROACT 1 may be used to support both accelerated and confirmatory approval of rilparencelProKidney continues to maintain its ongoing dialogue with the FDA under rilparencel’s RMAT designation
Publications & Presentations

January 2026: Phase 2 REGEN-007 results published in the Clinical Journal of the American Society of Nephrology (CJASN)November 2025: Phase 2 REGEN-007 results presented as a late-breaking clinical trial at ASN Kidney Week Key Clinical Takeaway
The Company has achieved FDA alignment on the accelerated and confirmatory approval pathways for rilparencel. Completion of PROACT 1 enrollment this year is a key 2026 milestone. The positive Phase 2 REGEN-007 results provide confidence heading into the expected pivotal topline results (eGFR slope) in the second quarter of 2027.

First Quarter 2026 Financial Highlights

Liquidity: Cash, cash equivalents and marketable securities as of March 31, 2026, totaled $224.9 million, compared to $270.0 million as of December 31, 2025. We expect that our existing cash, cash equivalents and marketable securities held at March 31, 2026, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027.

R&D Expenses: Research and development expenses were $33.8 million for the three months ended March 31, 2026, compared to $27.3 million for the same period in 2025. The increase of $6.6 million was driven primarily by increases in clinical study and related manufacturing costs of $6.5 million related to our ongoing PROACT 1 study. Additionally, compensation costs increased $1.2 million related to the hiring of additional personnel to support our operations. These increases have been offset by decreases in costs of $1.6 million related to clinical study costs for trials that have been completed or terminated.

G&A Expenses: General and administrative expenses were $11.3 million for the three months ended March 31, 2026 compared to $14.4 million for the same period in 2025. The decrease of $3.1 million was driven primarily by decreases in compensation costs of approximately $1.7 million due to vesting of awards issued prior to the business combination coupled with forfeitures of equity-based awards and reductions in severance costs. Additionally, professional fees and other operating costs have decreased $1.4 million driven by ongoing initiatives, including the domestication and restructuring transactions in 2025.

Net Loss Before Noncontrolling Interest: Net loss before noncontrolling interest was $42.6 million and $38.0 million for the three months ended March 31, 2026, and 2025, respectively.

Shares Outstanding: Class A and Class B common stock outstanding at March 31, 2026, totaled 301,953,977.

About Chronic Kidney Disease

CKD is a progressive condition characterized by the gradual decline of kidney function, which can ultimately lead to end-stage kidney disease (ESKD) requiring dialysis or transplantation. An estimated 37 million adults in the U.S. have CKD, though many remain undiagnosed in the early stages. Diabetes is the leading cause of CKD, and individuals with both conditions face significantly elevated risks of cardiovascular events, hospitalization, and mortality. ProKidney is developing rilparencel for patients with Stage 3b/4 CKD and diabetes, a population that includes over 1 million people in the U.S. While current treatment options aim to slow disease progression, there remains a substantial unmet need for therapies that can stabilize kidney function and delay or prevent the need for dialysis in patients with advanced CKD.

About the Phase 2 REGEN-007 Clinical Trial
REGEN-007 was a multi-center Phase 2 open-label 1:1 randomized two-armed trial in patients with diabetes and CKD who have an eGFR of 20-50 mL/min/1.73m². At randomization, patients were assigned to one of two treatment groups using different dosing regimens. Group 1 replicated the dosing schedule of the ongoing Phase 3 PROACT 1 study in which patients received two scheduled rilparencel injections (one in each kidney), approximately three months apart. Group 2 tested an exploratory dosing regimen to investigate whether disease progression triggers, rather than a time-based trigger, could optimize multiple administrations of rilparencel. In Group 2, patients received a single rilparencel injection in one kidney and a second injection in the contralateral kidney only if triggered by a sustained eGFR decline from baseline of ≥ 20%, and/or an increase of ≥ 30% and ≥ 30 mg/g in the urine albumin to creatinine ratio (UACR) from baseline. The purpose of this study was to assess the safety, efficacy, and durability of up to two rilparencel injections on renal function progression.

About the Phase 3 REGEN-006 (PROACT 1) Clinical Trial

REGEN-006 is an ongoing Phase 3, randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with advanced CKD and type 2 diabetes. The study protocol was amended in 1H 2024 to focus on a subset of patients with Stage 4 CKD (eGFR 20-30 mL/min/1.73m2) and late Stage 3b CKD (eGFR 30-35 mL/min/1.73m2) with accompanying albuminuria (UACR less than 5,000 mg/g for patients with eGFR 20-30 mL/min/1.73m2 and 300-5,000 mg/g for patients with eGFR 30-35 mL/min/1.73m2). The total planned enrollment is approximately 470 subjects. Subjects are randomized (1:1) to the treatment group and the sham control group prior to kidney biopsy or a sham biopsy procedure, respectively. The primary objective is to assess the efficacy of up to two rilparencel injections (one in each kidney) using a minimally invasive percutaneous approach. The surrogate endpoint for accelerated approval is eGFR slope, and the primary composite endpoint is the time from first injection to the earliest of: at least 40% reduction in eGFR; eGFR <15 mL/min/1.73m², and/or chronic dialysis, and/or renal transplant; or renal or cardiovascular death.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s PROACT 1 trial and other milestones provided, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

ProKidney Contact
Ethan Holdaway
[email protected]

ProKidney Corp. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except for share data)
       March 31, 2026  December 31, 2025  (Unaudited)    Assets     Cash and cash equivalents$101,895  $108,537 Marketable securities 123,049   161,480 Interest receivable 1,032   1,127 Prepaid assets 3,083   2,808 Prepaid clinical 4,049   3,923 Other current assets 1,794   2,804 Total current assets 234,902   280,679       Fixed assets, net 54,441   51,231 Right of use assets, net 3,441   3,664 Total assets$292,784  $335,574       Liabilities and Stockholders' Deficit     Accounts payable$2,592  $940 Lease liabilities 1,108   1,071 Accrued expenses and other 22,231   28,731 Income taxes payable –   – Total current liabilities 25,931   30,742       Income tax payable, net of current portion 1,074   1,074 Lease liabilities, net of current portion 2,675   2,965 Total liabilities 29,680   34,781 Commitments and contingencies     Redeemable noncontrolling interest 1,286,887   1,311,990       Stockholders’ deficit     Class A common stock, $0.0001 par value; 700,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 141,980,643 and 141,807,277 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 14   14 Class B common stock, $0.0001 par value; 500,000,000 shares authorized; 159,973,334 and 159,262,779 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 16   16 Additional paid-in capital 266,112   258,552 Accumulated other comprehensive (loss) gain (53)  56 Accumulated deficit (1,289,872)  (1,269,835)Total stockholders' deficit (1,023,783)  (1,011,197)Total liabilities and stockholders' deficit$292,784  $335,574  ProKidney Corp. and Subsidiaries
Consolidated Statements of Operations - Unaudited
(in thousands, except for share and per share data)
    Three Months Ended March 31,  2026  2025 Revenue$226  $230       Operating expenses     Research and development 33,842   27,263 General and administrative 11,317   14,355 Total operating expenses 45,159   41,618 Operating loss (44,933)  (41,388)      Other income (expense):     Interest income 2,327   4,027 Interest expense (15)  – Net loss before income taxes (42,621)  (37,361)Income tax expense —   591 Net loss before noncontrolling interest (42,621)  (37,952)Net loss attributable to noncontrolling interest (22,584)  (21,218)Net loss available to Class A common stockholders$(20,037) $(16,734)      Weighted average shares of Class A common stock outstanding:     Basic and diluted 141,925,099   126,976,366 Net loss per share attributable to Class A common stock:     Basic and diluted$(0.14) $(0.13) ProKidney Corp. and Subsidiaries
Consolidated Statements of Cash Flows – Unaudited
(in thousands)
    Three Months Ended March 31,  2026  2025 Cash flows from operating activities     Net loss before noncontrolling interest$(42,621) $(37,952)Adjustments to reconcile net loss before noncontrolling interest to net cash flows used
in operating activities:     Depreciation and amortization 1,658   1,600 Equity-based compensation 4,945   6,416 Gain on marketable securities, net (413)  (1,069)Loss on disposal of equipment –   300 Changes in operating assets and liabilities     Interest receivable 95   695 Prepaid and other assets 609   5,729 Accounts payable and accrued expenses (5,957)  (5,902)Income taxes payable –   591 Net cash flows used in operating activities (41,684)  (29,592)      Cash flows from investing activities     Purchases of marketable securities (44,754)  (55,449)Sales and maturities of marketable securities 83,366   84,873 Purchase of equipment and facility expansion (3,785)  (1,135)Net cash flows provided by investing activities 34,827   28,289       Cash flows from financing activities     Proceeds from sales of Class A common stock, net of offering costs 7   – Payments on finance leases (3)  (12)Exercise of stock options 211   – Net cash flows provided by (used in) financing activities 215   (12)      Net change in cash and cash equivalents (6,642)  (1,315)Cash, beginning of period 108,537   99,120 Cash, end of period$101,895  $97,805       Supplemental disclosure of non-cash investing and financing activities:     Right of use assets obtained in exchange for lease obligations$–  $322 Exchange of Class B common stock$26  $2,418 Impact of equity transactions and compensation on redeemable noncontrolling interest$2,366  $4,426 Equipment and facility expansion included in accounts payable and
accrued expenses$859  $1,653 

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel June 02, 2026 08:00 ET  | Source: ProKidney

WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer.

“Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies,” said Bruce Culleton, M.D., CEO of ProKidney. “As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success.”

Mr. Locke joins ProKidney from Carisma Therapeutics, where he oversaw CMC, Quality and Regulatory functions and led technical strategy for first-in-human CAR Myeloid programs. He built and scaled teams to support clinical development and contributed to strategic asset transitions through licensing and technology transfer of cell and viral vector manufacturing processes.

Previously, he held leadership roles at Celgene (now Bristol Myers Squibb), where he led external manufacturing and strategic sourcing for cell therapy programs, and at Novartis, where he helped advance early-stage cell therapy programs and established global capabilities across manufacturing and supply chain.

“The opportunity to help advance a first-in-class autologous cell therapy for patients with severe chronic kidney disease is incredibly compelling,” said Mr. Locke. “ProKidney has built a strong foundation with its in-house manufacturing capabilities and expertise in kidney disease, and I’m energized to work with this talented team as we execute on our Phase 3 study and prepare for the next stage of growth.”

Mr. Locke began his career in research and procurement roles of increasing responsibility at Bristol Myers Squibb and other biopharmaceutical organizations. He holds a Master of Science in Molecular Biology from Lehigh University and a Bachelor of Science in Biology Education from Millersville University of Pennsylvania.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s PROACT 1 trial and other milestones provided, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

ProKidney Contact
Ethan Holdaway
[email protected]

MILWAUKEE--(BUSINESS WIRE)--LiveWire Group, Inc. (“LiveWire” or the “Company”) (NYSE: LVWR) today reported first quarter 2026 results.

“We ended the first quarter of 2026 with an 86% increase in revenue over prior year, driving improved gross profit and operating loss, and a 25% improvement in free cash flow, compared to first quarter 2025. We also maintained our position as the number one retailer of U.S. electric on-road motorcycles1. With the upcoming launch of the S4 Honcho™, we are excited about the continued positive strides to be made in the business in the remainder of 2026,” said Karim Donnez, CEO, LiveWire.

First Quarter Highlights and Financial Results

Electric Motorcycle unit sales increased 176% over first quarter 2025 with revenue increasing 236%. STACYC unit sales increased 101% over first quarter 2025 with revenue increasing 60%. Consolidated operating loss decreased by $3.0 million from same quarter 2025 driven by an improvement in gross profit of $1.6 million and decrease in consolidated selling, administrative and engineering expense of $1.4 million. Reduced net cash used by operating activities by 26% driving a 25% improvement in free cash flow as compared to 2025. Market share of 76% in the U.S. electric motorcycle 50+kilowatt on-road EV segment1. Targeted production of the S4 Honcho™ continues to be in Spring 2026. Total Company Highlights

$ in millions*

1st quarter

2026

2025

Change

Consolidated Revenue Units

4,050

2,003

102%

Consolidated Revenue

$5.1

$2.7

86%

Consolidated Operating Loss

($17.7)

($20.7)

14%

Net Loss

($18.1)

($19.3)

6%

Free Cash Flow**

($13.6)

($18.1)

25%

*Amounts may not add or recalculate due to rounding.

**Definition of Free Cash Flow and reconciliation to the comparable GAAP metrics is at the end of this release.

The Company’s consolidated net loss was $18.1 million for the first quarter 2026 as compared to $19.3 million in the same period prior year driven by the segment results noted below, offset by an increase of $1.4 million in related party interest expense, and a decrease of $0.5 million of non-operating income related to the change in fair value of the outstanding warrants as of March 31, 2026 as compared to prior year.

LiveWire Group, Inc. is comprised of two business segments:

STACYC – focused on the sale of electric balance bikes for kids, electric bikes, and related products Electric Motorcycles – focused on the sale of electric motorcycles and related products STACYC

$ in millions*

1st quarter

2026

2025

Change

Electric Balance Bike and Electric Bike Units

3,959

1,970

101%

Revenue

$3.7

$2.3

60%

Operating Loss

($1.0)

($1.3)

26%

*Amounts may not add or recalculate due to rounding.

STACYC unit sales increased by 101% compared to the prior year same quarter resulting in an increase to revenue of $1.4 million. Operating loss decreased by $0.3 million in the first quarter of 2026 compared to 2025 primarily due to increased gross profit on increased sales.

Electric Motorcycles

$ in millions*

1st quarter

2026

2025

Change

Motorcycle Units

91

33

176%

Revenue

$1.4

$0.4

236%

Operating Loss

($16.7)

($19.4)

14%

*Amounts may not add or recalculate due to rounding.

Electric Motorcycle unit sales increased by 176% compared to the prior year same quarter resulting in an increase to revenue of $1.0 million. Operating loss decreased by $2.7 million primarily driven by a $1.6 million reduction in selling, administrative and engineering expense from continued focus on cost reduction, primarily people costs, compared to the same quarter in the prior year.

Financial guidance

For the full year 2026, the Company reiterates its full-year guidance.

Webcast

The public is invited to attend Harley-Davidson, Inc.’s audio webcast from 8-9:30 a.m. CT where discussion of LiveWire will be limited to financial results and updates to LiveWire’s outlook. The webcast login can be accessed at https://investor.livewire.com/news-events-1/events/default.aspx. The audio replay will be available by approximately 10:00 a.m. CT.

About LiveWire

LiveWire has a dedicated focus on the electric motorcycle sector. LiveWire’s majority shareholder is Harley-Davidson, Inc. LiveWire comes from the lineage of Harley-Davidson and is capitalizing on a decade of its learnings in the EV sector. With a dedicated focus on EV, LiveWire plans to develop the technology of the future and to invest in the capabilities needed to lead the transformation of motorcycling. www.livewire.com

Cautionary Note Regarding Forward-Looking Statements

The Company intends that certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Words or phrases such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “is on track,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “remain committed,” “should,” “target,” “will” and “would,” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the risks, uncertainties and assumptions described in prior public filings titled “Risk Factors.” These forward-looking statements are subject to numerous risks, including, without limitation, the following: our history of losses and expectation to incur significant expenses and continuing losses for the foreseeable future; Harley-Davidson, Inc. (“H-D”) making decisions for its overall benefit that could negatively impact our overall business; our relationship with H-D and its impact on our other business relationships; our ability to obtain funding for our operations, access to capital markets and manage costs; our future capital requirements and sources and uses of cash; our limited operating history, the rollout of our business and the timing of expected business milestones, including our ability to develop and manufacture electric vehicles of sufficient quality and appeal to customers on schedule and on a large scale; our financial and business performance, including financial projections and business metrics and any underlying assumptions thereunder; changes in our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans, including our ability to effectively execute the Company’s relocation and streamlined headcount plan within expected costs and time and our ability to realize the expected savings on an ongoing annual basis; our ability to manage and predict the impact of global trade issues and changes in and uncertainties with respect to trade and export regulations, trade policies and sanctions, tariffs, international trade disputes, particularly those relating to China and Taiwan, may have on the Company's ability to sell products domestically and internationally, and the cost of raw materials and components, including tariffs recently imposed or that may be imposed by the U.S. on foreign goods or other tariffs recently imposed or that may be imposed by foreign countries on U.S. goods; retail partners being unwilling to participate in our go-to-market business model or their inability to establish or maintain relationships with customers for our electric vehicles; our ability to attract and retain a large number of customers; challenges we face as a pioneer into the highly-competitive and rapidly evolving electric vehicle industry; our operational and financial risks if we fail to effectively and appropriately separate the LiveWire business from the H-D business; our ability to leverage contract manufacturers, including H-D and Kwang Yang Motor Co., Ltd., a Taiwanese company (“KYMCO”), to contract manufacture our electric vehicles; potential delays in the design, manufacture, financing, regulatory approval, launch and delivery of our electric vehicles; building out our supply chain, including our dependency on our existing suppliers and our ability to source suppliers, in each case many of which are single-sourced or limited-source suppliers, for our critical components such as batteries and semiconductor chips; global trade issues and changes in and uncertainties with respect to trade and export regulations, trade policies, sanctions, tariffs, international trade disputes, particularly those relating to China or Taiwan, geopolitical events and related actions that may occur between mainland China and Taiwan; increased geopolitical volatility and conflicts, such as in the Middle East, our ability to rely on third-party and public charging networks; our ability to attract and retain key personnel; our business, expansion plans and opportunities, including our ability to scale our operations and manage our future growth effectively; the effects on our future business of competition, the pace and depth of electric vehicle adoption generally and our ability to achieve planned competitive advantages with respect to our electric vehicles and products, including with respect to reliability, safety and efficiency; our business and H-D’s business overlapping and being perceived as competitors; our inability to maintain a strong relationship with H-D or to resolve favorably any disputes that may arise between us and H-D; our dependency on H-D for a number of services, including services relating to quality and safety testing. If those service arrangements terminate, it may require significant investment for us to build our own safety and testing facilities, or we may be required to obtain such services from another third-party at increased costs; any decision by us to electrify H-D products, or the products of any other company; our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; potential harm caused by misappropriation of our data and compromises in cybersecurity; changes in laws, regulatory requirements, governmental incentives and fuel and energy prices; the impact of health epidemics on our business, the other risks we face and the actions we may take in response thereto; litigation, regulatory proceedings, complaints, product liability claims and/or adverse publicity; and the possibility that we may be adversely affected by other economic, business and/or competitive factors. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. Some of these risks and uncertainties may in the future be amplified by new risk factors and uncertainties that may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. You should read this earnings release completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

LiveWire Group, Inc.
Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

  Three months ended

March 31,
2026

March 31,
2025

Revenue, net

$

5,115

$

2,743

Costs and expenses:

Cost of goods sold

5,652

4,911

Selling, administrative and engineering expense

17,135

18,498

Total operating costs and expenses

22,787

23,409

Operating loss

(17,672

)

(20,666

)

Interest expense, related party

(1,417

)

—

Interest income

603

504

Change in fair value of warrant liabilities

383

905

Loss before income taxes

(18,103

)

(19,257

)

Income tax provision

25

14

Net loss

$

(18,128

)

$

(19,271

)

Net loss per share, basic and diluted

$

(0.09

)

$

(0.09

)

Weighted-average shares, basic and diluted

204,491

203,480

LiveWire Group, Inc.

Consolidated Balance Sheets

(In thousands)

  (Unaudited)

March 31,
2026

December 31,
2025

ASSETS

Current assets:

Cash and cash equivalents

$

67,495

$

82,777

Accounts receivable, net

3,120

3,383

Accounts receivable from related party

1

585

Inventories, net

14,225

15,255

Other current assets

2,959

2,887

Total current assets

87,800

104,887

Property, plant and equipment, net

26,495

27,556

Goodwill

8,327

8,327

Deferred tax assets

6

6

Lease assets

715

823

Intangible assets, net

741

804

Other long-term assets

3,539

4,008

Total assets

$

127,623

$

146,411

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

2,905

$

2,299

Accounts payable to related party

7,617

6,716

Accrued liabilities

9,693

12,362

Current portion of lease liabilities

240

496

Current portion of term loan - related party, net

—

800

Total current liabilities

20,455

22,673

Long-term portion of lease liabilities

365

246

Deferred tax liabilities

158

149

Long-term portion of term loan - related party, net

74,185

74,183

Warrant liabilities

1,518

1,901

Other long-term liabilities

2,626

1,231

Total liabilities

99,307

100,383

Shareholders' equity:

Preferred Stock

—

—

Common Stock

21

20

Treasury Stock

(5,244

)

(4,437

)

Additional paid-in-capital

352,711

351,489

Accumulated deficit

(319,155

)

(301,027

)

Accumulated other comprehensive (loss) income

(17

)

(17

)

Total shareholders' equity

28,316

46,028

Total liabilities and shareholders' equity

$

127,623

$

146,411

LiveWire Group, Inc.

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

  Three months ended

March 31,
2026

March 31,
2025

Cash flows from operating activities:

Net loss

$

(18,128

)

$

(19,271

)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation and amortization

2,415

3,085

Change in fair value of warrant liabilities

(383

)

(905

)

Stock compensation expense

1,222

1,615

Provision for expected credit losses

30

13

Deferred income taxes

8

12

Inventory write-down

318

809

Interest expense, related party

1,417

—

Other, net

(33

)

(199

)

Changes in current assets and liabilities:

Accounts receivable, net

215

239

Accounts receivable from related party

584

399

Inventories

698

(2,358

)

Other current assets

185

(155

)

Accounts payable and accrued liabilities

(2,443

)

(6,396

)

Accounts payable to related party

901

5,622

Net cash used by operating activities

(12,994

)

(17,490

)

Cash flows from investing activities:

Capital expenditures

(688

)

(613

)

Net cash used by investing activities

(688

)

(613

)

Cash flows from financing activities:

Payment of borrowings under term loan - related party

(800

)

—

Repurchase of common stock

(807

)

(250

)

Net cash provided (used) by financing activities

(1,607

)

(250

)

Effect of exchange rate changes on cash and cash equivalents

7

138

Net increase (decrease) in cash and cash equivalents

$

(15,282

)

$

(18,215

)

Cash and cash equivalents:

Cash and cash equivalents—beginning of period

$

82,777

$

64,437

Net increase (decrease) in cash and cash equivalents

(15,282

)

(18,215

)

Cash and cash equivalents—end of period

$

67,495

$

46,222

LiveWire Group, Inc. 
Free Cash Flow

We use free cash flow, which is a non-GAAP liquidity measure, to supplement our cash used by operating activities as presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”). We believe free cash flow is useful in evaluating our liquidity, as it is similar to measures widely used by certain investors, securities analysts and other interested parties as a supplemental measure of performance and liquidity. We also use this measure internally to establish forecasts, budgets and operational goals to manage and monitor our liquidity. This non-GAAP financial measure may not be comparable to other similarly titled measures of other companies, have limitations as analytical tools, and should not be considered in isolation or as a substitute for analysis of our operating results as reported in accordance with GAAP.

We define free cash flow as net cash used by operating activities, excluding cash paid for ongoing costs related to the Company’s At-The-Market (“ATM”) program which results in financing cash inflows, less capital expenditures.

Three months ended

March 31,
2026

March 31,
2025

Net cash used by operating activities

($12,994)

($17,490)

Cash paid for ongoing ATM costs

51

—

Less: Capital expenditures

(688)

(613)

Free cash flow

($13,631)

($18,103)

More News From LiveWire Group, Inc.

-

LiveWire expands further into the electric off‑road category with their first acquisition, combining complementary capabilities and accelerating product development.

MILWAUKEE--(BUSINESS WIRE)--LiveWire Group, Inc. (NYSE: LVWR), a leader in the electric two‑wheel industry, today announced it has acquired the assets of Dust Moto, bringing deep off‑road knowledge and expertise to LiveWire, thereby marking a strategic expansion into the electric off‑road segment.

The acquisition strengthens LiveWire’s strategy to grow beyond on‑road electric motorcycles and address the rapidly expanding electric off‑road market, which is being driven by riders seeking incredible torque and performance with the added benefits of reduced noise, lower maintenance, and an accessible riding experiences through simplified operation and single‑speed drive.

With the completed transaction, LiveWire is advancing Dust’s electric dirt bike platform toward production, leveraging LiveWire’s engineering capabilities, manufacturing scale, and global marketing, sales, and service network to accelerate development and go‑to‑market execution.

“LiveWire pioneered the on‑road electric motorcycle market, and this acquisition allows us to build on that leadership as we expand into off‑road, continuing the journey that began with STACYC ten years ago,” said Karim Donnez, CEO of LiveWire Group, Inc. “Dust Moto is a strong strategic fit and an accelerator of our vision, bringing proven off‑road insight that will contribute meaningfully to LiveWire’s leadership position in electric powersports.”

“Joining LiveWire marks an exciting next chapter in our journey,” said Colin Godby, CEO of Dust Moto. “LiveWire shares our fundamental DNA as an American brand focused on performance, innovation, and putting riders first. With LiveWire’s scale, resources, and global reach, we can bring our electric off-road bike to market with a worldwide audience and deliver an unmatched off-road experience.”

The acquisition reflects LiveWire’s continued focus on expanding its product portfolio and addressable market while reinforcing its commitment to innovation across electric powersports. LiveWire intends to share more information on the launch of the product in the second half (2H) of this year.

About LiveWire

LiveWire has a dedicated focus on the electric powersports sector. LiveWire’s majority stockholder is Harley-Davidson, Inc. LiveWire comes from the lineage of Harley-Davidson and is capitalizing on a decade of its learnings in the EV sector. LiveWire plans to develop the technology of the future and invest in the capabilities needed to lead the transformation of motorcycling and powersports.

About Dust Moto

Dust Moto, a pioneering electric motorcycle startup in the U.S., launched with the intention of offering an affordable, high performance electric dirt bike.

More News From LiveWire Group, Inc.

Back to Newsroom

, /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication of a new study comparing its VASCADE MVP® XL vascular closure system with the VASCADE MVP® venous vascular closure system in the context of large‐bore venous access closure procedures. This study, "VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Single-Center Experience on Efficacy and Complications," was published earlier this week in the Journal of Cardiovascular Electrophysiology.

The retrospective, non‐randomized, observational single‐center cohort study included a total of 574 consecutive patients undergoing catheter ablation for atrial arrhythmia, or left atrial appendage closure procedures. The study included some procedures in which VASCADE MVP was used outside the scope of its approved indication, which is for use with 6-12F inner diameter procedural sheaths. Results demonstrated VASCADE MVP XL's superior performance in the context of these large‐bore venous access closure procedures, achieving higher procedural success, a more consistent safety profile, and efficient hemostasis without complications, including 0% bleeding complications.

In March 2026, the U.S. Food and Drug Administration (FDA) approved expanded labeling for the VASCADE MVP XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation (PFA) to treat atrial fibrillation such as Boston Scientific's FARAPULSE® and left atrial appendage closure (LAAC) solutions, including Boston Scientific's WATCHMAN TruSteer®. VASCADE MVP XL is now the only extravascular venous closure system clinically proven in electrophysiology procedures using up to 17F OD procedural sheaths.

FDA approval was supported by clinical evidence from the AMBULATE EXPAND trial, a multicenter, prospective, single-arm, pivotal trial designed to evaluate the safety and effectiveness in technologies using 17F maximum OD procedural sheaths. The study results were published in the Journal of Cardiovascular Electrophysiology in March 2026. Additionally, findings from a prospective ultrasound sub‑study involving 31 patients were published in Heart Rhythm O2 yesterday and will be presented at the Heart Rhythm Society's Heart Rhythm 2026 in Chicago on Saturday, April 25, 2026 from 12:00 – 2:00 p.m. CT. This study provided an imaging‑based assessment of the closure site and demonstrated encouraging early vascular findings in a high‑risk, fully anticoagulated population, offering further insight into vascular healing following VASCADE MVP XL deployment.

"The expanded indication for the VASCADE MVP® XL system supports the rapidly evolving electrophysiology landscape, including the adoption of next‑generation PFA and LAAC technologies and the growing number of concomitant procedures," said Jan Hartmann, M.D., Senior Vice President and Chief Medical Officer at Haemonetics. "By enabling reliable venous closure in large‑bore procedures, VASCADE MVP XL helps electrophysiology teams deliver safe, effective care across hospital‑based labs and increasingly time‑ and cost‑conscious outpatient settings, including ambulatory surgery centers."

Clinical data related to the VASCADE MVP XL system will be presented and discussed at HRS 2026, as part of a Haemonetics‑sponsored Rhythm Theater session entitled Efficient Workflows for AF Ablation: New Technologies and Sites of Service, scheduled for Saturday, April 25, 2026, at 10:30 a.m. CT.

About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

Cautionary Statement Regarding Forward-Looking Information

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding plans and objectives of management for the operation of Haemonetics, including statements regarding potential benefits associated with the expanded labeling of the VASCADE MVP XL venous vascular closure system and Haemonetics' plans or objectives related to the commercialization of such product enhancement. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics' current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, product quality; market acceptance; the effect of economic and political conditions; and the impact of competitive products and pricing. These and other factors are identified and described in more detail in Haemonetics' periodic reports and other filings with the U.S. Securities and Exchange Commission. Haemonetics does not undertake to update these forward-looking statements.

Investor Contacts:     

Olga Guyette, Vice President-Investor Relations & Treasury 

David Trenk, Manager-Investor Relations

(781) 356-9763   

(203) 733-4987

[email protected]  

[email protected]

Media Contact:  

Josh Gitelson, Sr. Director-Global Communications   

(781) 356-9776

[email protected] 

SOURCE Haemonetics Corporation

Financial release and supplemental presentation accessible online

, /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 7, 2026.

Conference Call and Webcast Information:

Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended. Live webcast: Access here or through the Investor Relations section of the Haemonetics website. A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on May 7, 2026 and will remain accessible for one year via the webcast link above.

Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:

Fourth Quarter Fiscal 2026 Earnings Release Fourth Quarter Fiscal 2026 Supplemental Earnings Presentation ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.        

Investor Contacts:
Olga Guyette, Vice President-Investor Relations & Treasury
(781) 356-9763
[email protected] 

David Trenk, Manager-Investor Relations
(203) 733-4987
[email protected]                                                                                

Media Contact:
Josh Gitelson, Sr. Director-Global Communications 
(781) 356-9776
[email protected] 

SOURCE Haemonetics Corporation

Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.